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Graphical Abstract
TERCELOI clinical trial addresses fundamental issues concerning the feasibility,
security and potential of 5MSCs infusions in two non immunosuppressedOsteo-
genesis Imperfecta pediatric patients. This trial allowed us to elucidate themech-
anism of action of MSCs therapy, characterized by a pro-osteogenic paracrine
response. For that, we studied the protein andmiRNA levels in sera frompatients
(collected before, along and after the cell treatment) besides unraveling the tran-
scriptomic alterations due to those sera presence, and demonstrating their func-
tional capabilities.
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Background: Osteogenesis imperfecta (OI) is a rare genetic disease character-
ized by bone fragility, with a wide range in the severity of clinical manifesta-
tions. Themajority of cases are due tomutations in theCOL1A1 orCOL1A2 genes,
which encode type I collagen. Mesenchymal stem cells (MSCs), as the progeni-
tors of the osteoblasts, the main type I collagen secreting cell type in the bone,
have been proposed and tested as an innovative therapy for OI with promising
but transient outcomes.
Methods: To overcome the short-term effect of MSCs therapy, we performed
a phase I clinical trial based on reiterative infusions of histocompatible MSCs,
administered in a 2.5-year period, in two pediatric patients affected by severe
and moderate OI. The aim of this study was to assess the safety and effectiveness
of this cell therapy in nonimmunosuppressed OI patients. The host response to
MSCs was studied by analyzing the sera from OI patients, collected before, dur-
ing, and after the cell therapy.
Results:We first demonstrated that the sequential administration of MSCs was
safe and improved the bone parameters and quality of life of OI patients along
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the cell treatment plus 2-year follow-up period. Moreover, the study of themech-
anism of action indicated that MSCs therapy elicited a pro-osteogenic paracrine
response in patients, especially noticeable in the patient affected by severe OI.
Conclusions:Our results demonstrate the feasibility and potential of reiterative
MSCs infusion for two pediatric OI and highlight the paracrine response shown
by patients as a consequence of MSCs treatment.
KEYWORDS
cell therapy, mesenchymal stem cell, paracrine mechanism of action, regenerative medicine
1 BACKGROUND
Osteogenesis imperfecta (OI), with an estimated incidence
of 1 in 10 000-20 000 births, is a rare connective tissue disor-
der affectingmainly the bones, which are extremely fragile
due to low bone mass.1 OI is a highly clinically and geneti-
cally heterogeneous disorder.2 To date, mutations in 19 dif-
ferent genes have been described to cause OI with a wide
range of clinical severity from mild to severe/lethal OI.3–5
The majority of cases (up to 90% of individuals) are caused
by dominant mutations in the COL1A1 or COL1A2 genes.6
These genes code for collagen type I, the main extracel-
lular matrix protein of bone that is composed of two α1
chains and one α2 chain to form a triple helix molecule.7
The severity of OI patients with COL1A1 or COL1A2 as
causative genes depends on the nature of type I collagen
mutations.8–12 Thus, mutations that lead to quantitative
collagen defects result in structurally normal type I col-
lagen at decreased levels, and are associated with a mild
clinical phenotype. On the contrary, mutations leading to
structural defects of type I collagen disrupt the folding of
the triple helix and are associated with moderate-severe-
lethal phenotypes. The remaining OI cases (∼10%), with
moderate-to-severe clinical phenotypes, are originated by
mutations in noncollagenous genes that encode proteins
with crucial roles in collagen folding and posttranslational
modifications, osteoblasts differentiation, and bonematrix
mineralization.1 Moderate and severe OI patients suffer
multiple low-trauma fractures throughout their lifetime
along with short height, skeletal deformities, and chronic
pain. Because type I collagen is expressed in many tissues,
extraskeletal manifestations are also common in these
patients.13
Currently there is no cure for OI and the existing options
are aimed at improving symptoms. Orthopedic surgery
has been postulated as fundamental not only in the treat-
ment of fractures, to strengthen the bone with mechanical
measures, but to diminish the bone deformities associated
with the disease.13 In the case of pediatric patients, phar-
macological interventions such as antiresorptive drugs
(mainly bisphosphonates) are focused on increasing bone
mineral density (BMD) and decreasing pain.13,14 This
shortage of treatment options led Horwitz and coworkers
to address a new therapeutic strategy based on mesenchy-
mal stem cells (MSCs) transplantation into OI pediatric
patients who previously were immunosuppressed.15,16 The
rationale for this approach was that after transplantation,
the MSCs as the progenitors of osteoblasts would engraft
in host tissues, differentiate into functional osteoblasts,
and secrete normal collagen type I. This would ameliorate
the symptoms associated with OI, as previously demon-
strated in preclinical studies.17 Moreover, the reported
cases of asymptomatic mosaic carriers of OI mutations
supported this assumption, suggesting that having low
amounts of cells with normal collagen would be enough to
rescue or at least ameliorate OI pathological phenotypes.18
Notably, after cell therapy OI pediatric patients showed
improvements in terms of growth velocity and fracture fre-
quency, but these beneficial effects were transitory and the
expected cell engraftment into bone tissue was anecdotal.
Later studies addressing prenatal transplantation of fetal
MSCs to OI patients also reported similar outcomes.19,20
Thus, both prenatal and postnatal administration of MSCs
inOI (one or twoMSCs infusions) have been demonstrated
to be feasible and safe, exerting clinical improvements
of OI phenotypes, in spite of being short-lived.15,16,19 The
detailed mechanisms underlying the beneficial effects of
MSCs therapy in OI are still unclear but the possibility
of a paracrine therapeutic effect of MSCs is gaining
attention.21,22 However, there is no in vivo study exploring
the trophic effects induced in OI patients byMSCs therapy.
Given the transitory effect of MSCs therapy in OI pedi-
atric patients, we considered multiple histocompatible
MSCs infusions with same-donor cells as a strategy to
improve cell therapy outcomes in OI patients. Thus, we
conducted an independent, multicenter cell therapy phase
I clinical trial based on reiterative infusions of nonmutated
HLA-identical or histocompatible (at least five shared out
of six HLA antigens) allogenic MSCs applied to two OI
pediatric patients. The principal aim of this trial was to
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assess the safety and secondarily the effectiveness of five
(5-6 months apart) MSCs infusions in OI patients irrespec-
tively of their treatmentwith bisphosphonates andwithout
subjecting them to any immunosuppressor treatment. At
the same time, this study also sought to gain insight into
the underlying paracrine mechanism induced by infused
MSCs in an OI scenario. Importantly, the present clinical
trial is the first, to the best of our knowledge, to explore
not only the effects of serial MSCs infusions but also the
mechanism of action of MSCs therapy in OI patients.
2 MATERIALS ANDMETHODS
2.1 Study design and patients
The Mesenchymal Stem Cell Therapy for the Treat-
ment of Osteogenesis Imperfecta (TERCELOI) study
was registered with clinicaltrials.gov (NCT02172885) and
eudract.ema.europa.eu (2012-002553-38). TERCELOI is an
independent multicenter phase I clinical trial to evaluate
the feasibility, safety, and potential efficacy of infused sib-
ling HLA-matched MSCs in nonimmunosuppressed chil-
drenwith OI. Inclusion and exclusion criteria are specified
in table 1 appearing in Figure 1A. Enrolled patients were
the following: P01, male, 6 years 1 month of age and P02,
female, 8 years and 1 month of age.
P01was born to a healthy andnonconsanguineous Span-
ish couple. Skeletal dysplasia was suspected at 24 weeks
of gestation. Cesarean delivery was at 34 weeks. At birth
weight: 1770 g (p9, –1.4 SD), length: 39 cm (p< 1, –3.38 SD),
and occipital frontal circumference (OFC): 30 cm (p3, –
1.96 SD). X-ray survey showedmultiple fractures involving
humeri, femur, tibia, and several ribs. A genetic study con-
firmed the clinical diagnosis of OI. A de novo heterozygous
missense mutation was identified in exon 16 of COL1A1
gene: c.1031G>A (p.Gly344Asp). The patient showed blue
sclera and developed dentinogenesis imperfecta. He had
normal neurodevelopment, sitting unsupported at the age
of 9 months. He could never achieve unaided standing up
or walking due to compression fractures of the spine and
limb deformity. The first orthopedic surgical intervention
was performed at the age of 4.5 years and consisted of cor-
rection of bilateral tibia angulation. Compassionate intra-
venous treatment with biphosphonates was initiated at the
age of 57 days. He was treated with pamidronate until the
age of 5 years and 4 months when zoledronate was pre-
scribed instead. Spontaneous fractures or with minimal
trauma and chronic bone pain have been common man-
ifestations due to the extreme bone fragility. P02 was the
first child born to a healthy and nonconsanguineous cou-
ple. Skeletal dysplasia was suspected at 34 weeks of ges-
tation. Cesarean breech delivery was at 38 weeks of ges-
tation. Weight: 2820 g (p 33; –0.44 SD) and OFC: 33 cm
(p28; –0.4 SD). OI was suspected at birth. She had blue
sclera, micrognathia, short lower limbs, and fracture of
one clavicle. X-ray skeletal assessment showed low bone
density and prenatal fracture of the contralateral clavicle,
eighth rib, and unilateral cubitus. Genetic studies identi-
fied a de novo heterozygous variant in the COL1A2 gene:
c.2133+6T>A resulting in the skipping of exon 35. At the
age of 2 months, the patient revealed severe generalized
osteopenia, and angulation of both femur and tibia with
several areas of sclerosis. Compassionate treatment with
pamidronate was initiated at the age of 15 months until the
age of 7 years and 10 months when zoledronate was pre-
scribed instead. She had normal social and language devel-
opment. She could walk at the age of 3 years. Recurrent
fractures of long bones of the upper and lower limbs lead-
ing to bone deformities required several surgical interven-
tions. Mobility was largely wheelchair dependent.
2.2 HLA typing
Genomic DNA was extracted from both recipients and
donors by peripheral blood using an automated method
(MagNA re, Roche, USA). A ready-to-use system of HLA
typing with PCR-SSO methodology and Luminex flow
analyzer technology was used to identify specific alle-
les present in a locus-specific PCR-amplified sample
(LIFECODES, Immucor, USA) at the HLA-A*, HLA-B*,
and DRB1* loci. PCR reactions were carried out in a Ver-
iti thermal cycler (Applied Biosystems, USA) according to
the manufacturer’s recommendations. The results of HLA
typing of each patient and donor (respectively) were as
follows:




P02/donor (5/6 match): HLA-A*02/*02; HLA-
A*03/*03; HLA-B*51/*51; HLA-B*51/*51; HLA-
DRB1*07/*07; HLA-DRB1*08/*14.
2.3 Isolation, characterization,
expansion, and infusions of sibling bone
marrowMSCs
HLA-haploidentical MSCs were isolated from bone mar-
row aspirates obtained from healthy siblings. The samples
were obtained at the Onco-Hematology Service of the
Niño Jesus Hospital in Madrid. The samples were trans-
ported following approved protocols to the Cell Produc-
tion Unit of the Foundation for Biomedical Research at the
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Gregorio Marañón Hospital (UPC-FIBHGM). MSCs were
obtained under GMP rules at the UPC-FIBHGM, with
GMP certificate ES/125I/18, following the protocols of 12–
088 IMPD approved by the Spanish Agency for Medicines
and Health Products (AEMPs). Once the BM aspirates
were received by the UPC-FIBHGM personnel and their
integrity was verified, the mononuclear cells (MNCs) were
obtained using a density gradient (Ficoll Paque Premium,
GEHealthcare, USA). The interface containingMNCs was
washed twice and osmotic shock was performed to remove
the remains of the Ficoll reagent and red cells, respec-
tively. Then the MNCs were cultured at a concentration of
160 × 105 cells/cm2 in complete DMEM medium (Gibco,
USA), supplemented with 10% fetal bovine serum (FBS)
(Gibco), and they were kept under standard culture con-
ditions (37◦C, 5% CO2, and 95% humidity). After 48 h,
the appearance of the layer was reviewed and a medium
change was carried out. This activity was performed every
3-4 days until the layer achieved a confluence of 80%. At
that point, the cells were harvested using Tryple Select fol-
lowing the guidelines of the manufacturer (Gibco). Cell
counts and calculation of cell viability were carried out,
and cells were subsequently seeded at a concentration of
5000 cells/cm2 to continue their expansion, repeating this
process until obtaining the necessary cell number for the
five doses applied to each patient, at a concentration of
4 × 106 cells/kg of body weight. During the process, the
following quality controls were carried out: cell count and
viability, sterility test, mycoplasma detection, and differ-
entiation potential (osteogenic, adipogenic, and chondro-
genic differentiation). In addition, samples were taken to
carry out the genetic stability analysis (CGHarray) in order
to have the result before releasing the doses. At the end of
the culture, the cells were harvested, and the final product
(FP)was prepared for infusion in the patients. For infusion,
the cells were resuspended in Ringer Lactate (BRAUN,
USA) supplemented with 1% human serum albumin. Cel-
lular samples were taken from the FP for immunopheno-
typic characterization and the retention sample. The FP
was packaged in a EVA bag (MacoPharma, USA) with a
final volume of 20 mL. Patients were infused under nonin-
vasive monitoring of vital signs. Each patient received five
infusions of 4 × 106 MSCs/kg each infusion, 5-6 months
apart.
2.4 Peripheral blood mononuclear cells
isolation and serum collection
Venous blood samples were collected before the cell ther-
apy (basal serum), during the cell therapy (1 week, 1
month, and 4 months after each MSCs infusion), and dur-
ing the follow-up period (1 and 2 years after the fifth and
last MSCs infusion). The peripheral blood mononuclear
cells (PBMCs) from TERCELOI patients were isolated by
Ficoll density gradient-based centrifugation (Lymphoprep,
Axis-Shield, Norway) following the manufacturer specifi-
cations at the specific time points indicated in the study
design. The serum samples were collected in Clot Activa-
tor tubes (BD Vacutainer) and left undisturbed for 40 min
at room temperature (RT) to allow the blood to clot. Then,
blood samples were centrifuged at 1300 × g at RT during 15
min to remove the clot. The resulting serum supernatant
was carefully transferred into a clean tube, aliquoted, and
stored at –80◦C until analysis.
2.5 Mixed lymphocyte reaction assay
PBMCs isolated from patients were resuspended in phos-
phate buffered saline (PBS) + FBS (5%) and stained with
carboxyfluorescein succinate ester (CFSE) (Molecular
Probes, USA) at a final concentration of 5 μM for 5
min, at RT in the dark. CFSE-stained PBMCs were then
washed three times with PBS + FBS (5%). To perform
the mixed lymphocyte reaction (MLR) assay, triplicate
samples of the CFSE-stained PBMCs were cultured in a
96-well plate (200 000 cells/well), where the MSCs from
HLA-matched siblings were seeded the day before (20 000
cells/well). The cells were cultured in complete RPMI
medium (Invitrogen, USA) for 5 days with or without
the presence of phytohemagglutinin (PHA). Cultures of
unstimulated (negative control) and PHA (Sigma-Aldrich,
USA)-stimulated PBMCs (2 μg/mL) were seeded without
the presence of MSCs. Each condition was seeded in
triplicate. After 5 days, the OI PBMCs were harvested,
stainedwith antihuman-CD3 antibody (BectonDickinson,
USA), and acquired by flow cytometry. Cell proliferation
was calculated using ModFit LT (Verity Software House,
USA). The parental generation was set with unstimulated
PBMCs, which show a unique peak of fluorescence. Then,
cell division was tracked by measuring dilution of CFSE
signal in stimulated cells.
2.6 Bone mineral density
BMD at the lumbar spine, from L1 to L4, was measured by
dual energy X-ray absorptiometry on a whole-body scan-
ner in a pediatric platform (Hologic QDR densitometer).
2.7 Assessment of bone microstructure
X-ray images from the femoral distal metaphysis of
patients were used to manually delineate a region of
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interest (ROI). This ROI was drawn by selecting only
the region where trabecular bone was present, that is,
avoiding cortical bone, metallic implants, and fracture cal-
lus. Once the ROI was delineated, signal heterogeneities
were corrected and through an Otsu’s thresholding algo-
rithm, the ROI was binarized separating trabecular bone
(foreground) from marrow (background). To characterize
bone microstructure, different morphological imaging
biomarkers (explained in Methods in the Supporting
Information) were automatically calculated from the ROI
by using Quibim Precision Software (QUIBIM, Valencia,
Spain).23–25 Bone volume to total volume (BV/TV) ratio
is the percentage of bone within the ROI. The number
of voxels corresponding to trabecular bone were divided
by the number of all the voxels (trabecular bone and
marrow). Mean trabecular bone thickness (TbTh) is the
mean thickness value of all the beams of trabecular bone
within the ROI. To calculate the trabecular thickness
on each pixel, a pipeline of different morphological and
level-based image processing techniques was applied
to the binary image. Mean trabecular bone separation
(TbSp) is the mean size of the intertrabecular spaces or
pores. Trabecular number (TbN) is the ratio between the
percentage of bone and the mean trabecular thickness.
Quality Trabecular Score (QTS) score was obtained from
a multivariate analysis based on principal component
analysis (PCA) over a population with previously defined
imaging biomarkers. This score assesses trabecular bone
quality, with lower values indicating a higher fracture risk.
2.8 Assessment of health-related
quality of life
Health-related quality of life (HRQoL) was assessed by
PedsQL version 4.0,which is a validatedmodular approach
to measuring HRQoL in healthy children and adoles-
cents (ages, 2-18) and those with acute and chronic health
conditions.26 The application of PedsQL has also been rec-
ommended by the Initiative on Methods, Measurement
and PainAssessment in Clinical Trials (IMMPACT).27 Ped-
sQoL 4.0 consists of 23 questions measuring the core
health dimensions delineated by World Health Organiza-
tion. Thus, it encompasses four domains: physical (eight
items), emotional (five items), social (five items), and
school (five items) functioning. We applied the question-
naire to patients (self-report) and parents (proxy-report).
Importantly, the items for self-report and proxy-report are
basically the same differing in developmentally appro-
priate language. The questions refer to the frequency of
problems that occurred during the past month. A 5-point
response scale is used to measure the items (0 = never
a problem, 1 = almost never a problem, 2 = sometimes
a problem, 3 = often a problem, and 4 = almost always
a problem). Then, items are reverse scored and lineally
transformed to a 0-100 scale (0= 100, 1= 75, 2= 50, 3= 25,





Sera from P01 and P02 collected before, during (1 week,
1 month, and 4 months after each MSCs infusion),
and after the cell therapy were used for human
glycosylphosphatidylinositol-specific phospholipase
D1 (GPLD1) detection. For this, human GPLD1 enzyme-
linked immunosorbent assay (ELISA) kit (FineTest,
China) was used with diluted sera samples (1:400), used
in duplicates, following manufacturer’s instructions.
2.10 Antibody array assay for serum
profiling
For antibody array experiments, sera from P01 and P02
collected before, 1 week, 1 month, and 4 months after
the first MSCs infusion were used. The relative expres-
sion of more than 1000 human serum proteins was
performed by using the RayBio Label-based (L-Series)
HumanAntibody Array 1000 kit (AAH-BLG-1000) accord-
ing to the manufacturer’s instructions (RayBiotech, USA).
Scanned images were captured using an Axon GenePix
laser scanner and analyzed using RayBio Analysis Tool
software. Protein intensities were obtained by taking the
average of the two spots specific to each protein, and
all protein intensities on a given array were normalized
against the blank, negative control, and positive control
spots.
2.11 MicroRNAs expression analysis
The expression of 21 circulating microRNAs (miRNAs)
related to bone quality and musculoskeletal diseases were
analyzed by using the OsteomiR test (TamiRNA GmbH,
Austria). Sera samples from TERCELOI patients before,
during (1 month after each cell infusion), and after the
cell therapy were used as starting materials to extract
miRNAs. Then, cDNA synthesis and Q-PCR were per-
formed. Importantly, for each step, specific controls were
used: unisp4 for the extraction step, nonhuman cel-miR-
39 for the cDNA synthesis, and Unisp3 IPC as an inter-
plate calibrator. The existence of hemolysis in the serum
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samples was excluded by studying the difference between
has-miR-451a and has-miR-23-3p. For normalization of
expression data, an RNAspike-in control was used. Raw
data were converted into Cq-values according to the sec-
ond derivativemethod and then transferred to theClustVis
online web tool for plotting the expression values as a
heatmap.
2.12 OI MSCs isolation and
characterization and culture
OI MSCs were derived from discarded and donated
bone fragments of OI pediatric patients (carrying muta-
tions in either COL1A1 or COL1A2) undergoing corrective
surgery. The donation was approved by the Basque Clin-
ical Research Ethics Committee. Briefly, bone chips were
mechanically flushed with PBS and then cut into small
pieces to extrude cells without the use of enzymes. The
bone pieces were left undisturbed during 14 days until
OI MSCs migrated to cell culture plate. OI MSCs were
assessed for the expression of CD105, CD90, and CD73
and the absence of CD14, CD34, CD45, CD19, and HLA-
DR and were also tested for their potential to differenti-
ate to osteoblasts and adipocytes using specific cell culture
media.
OI MSCs were cultured under standard growthmedium
(DMEM low glucose) with glutamax (Gibco, USA),
penicillin/streptomycin (Gibco), and fetal bovine serum
at 10% (Sigma-Aldrich, USA). Osteogenesis induction
medium (OIM) was composed of standard medium plus
ascorbic acid 0.2 mM, β-glycerophosphate 10 mM, and
dexamethasone 10 nM (all from Sigma-Aldrich). When
specified, FBS was replaced by P01 and P02 serum samples
at 2.5%.
2.13 RNAseq and Q-PCR validation
OI MSCs from 10 pediatric patients were seeded in 96-well
plates (1000 cells/well) and the following day cultured
in the presence of OIM. After 4 days of differentia-
tion, total RNA was isolated from cells with the AllPrep
DNA,RNA,MicroRNA extraction kit (QIAGEN, USA).
cDNA library (TrueSeq stranded Total cDNA library, Illu-
mina, USA) and sequencing at HiSeq 4000 (PE100nt, 50
million reads/sample) was performed byMacrogen (South
Korea). HISAT2 was used to align the RNA-seq reads for
each of the 20 samples to the human reference genome
GRCh38.28 Cufflinks was used to assemble the mapped
reads into possible transcripts and generate a transcrip-
tome assembly.29 The counts of aligned reads to each gene
were calculated with HTSeq.30 We used in-house software
to merge the expression results into a single text file used
in the downstream analysis in Matlab (MathWorks). We
performed quantile normalization to equalize the data and
stabilized them through the log2 transform of the data plus
one. The heatmap of the most highly variable transcripts,
the hierarchical clustering dendrograms (calculated using
the unweighted pair group method with arithmetic mean
and Euclidean distance measure), and the PCAs were
performed using in-home functions developed in Matlab
(MathWorks). We designed a democratic method to select
differentially expressed genes (DEGs) between the two
conditions: after the cell therapy versus before the cell ther-
apy. We searched for upregulated genes after treatment by
giving each gene a “for” vote in case of upregulation of
more than a threshold θvote in log2 scale in the after treat-
ment condition compared to the before treatment condi-
tion, and an “against” vote in case of downregulation of
more than θvote in log2 scale. We searched for downregu-
lated genes after treatment by giving each gene a “for” vote
in case there was a downregulation of more than θvote in
log2 scale in the after treatment condition compared to the
before treatment condition, and an “against” vote in case
of upregulation of more than θvote in log2 scale. Finally, we
chose all the genes with nine or more “for” votes for both
up- and downregulation. We used the P-value produced
by a tailed paired t-test to rank the selected genes. We
chose a threshold θvote = 0.1. To assay gene-coverage and
obtain track plots, we sorted the alignment bam files with
samtools and produced the bed files with the bedtools.31,32
We developed a function in Matlab (MathWorks) that for
each gene of interest takes the exon boundary information
from the basic annotation file in gtf format from gencode
(https://www.gencodegenes.org/human/) version 33, and
plots the gene-coverage count track plots, keeping for the
tracks of the same gene in all the samples the same scale.
The RNAseq data have been deposited in Gene Expression
Omnibus.
The same RNA samples used for RNAseq were used
for validation by Q-PCR. For this, 1 μg of the same RNA
used for RNAseq was reverse transcribed using the Super-
script III First Strand cDNA kit (Thermo Fisher Scien-
tific) according to the manufacturer’s instructions. For
each gene, all reactions were carried out in triplicate
on an AriaMX Real Time PCR System (Agilent, USA)
using Brilliant III Ultrafast SYBR Green Master mix (Agi-
lent). The program used consisted of denaturation of
the samples at 95◦C for 2 min, annealing step at 60◦C
for 30 s, and extension step at 72◦C for 30 s. For gene
expression normalization, GAPDH was used. The gene
expression levels were calculated using the ΔCT method
and are shown as the mean value with the standard
error of the mean. Primer sequences are available upon
request.
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2.14 Tissue nonspecific alkaline
phosphatase activity measurement
OI MSCs from eight pediatric patients were seeded in
quadruplicates in 96-well plates (1000 cells/well) and the
following day induced to differentiate in the presence of
OIM and serum (2.5%) from TERCELOI patients. After
4 days of differentiation, tissue nonspecific alkaline phos-
phatase (TNAP) activity was determined by adding to each
well a chromogenic substrate of alkaline phosphatase,
1-step PNPP substrate solution (Thermo Fisher Scientific,
USA) and absorbance was measured at 405 nm. To nor-
malize TNAP activity, cell number was determined by Cell
Counting Kit-8 (CCK-8, Bimake, USA) and absorbance
at 415 nm was measured in a parallel plate. As negative
controls, OI MSCs cultured under nondifferentiation
conditions were used.
2.15 Alizarin red S staining
OIMSCs from two pediatric patients were seeded in tripli-
cates in 12-well plates (15 000 cells/well) and the follow-
ing day induced to differentiate in the presence of OIM
supplemented with serum samples obtained from TER-
CELOI patients at 2.5%. Medium was changed twice per
week. After 14 days, mineralization was assessed by stain-
ing the extracellular calcium deposits. Cells were fixed
with 4% paraformaldehyde (Sigma-Aldrich) and stained
with alizarin red S staining (Thermo Fisher Scientific) (2%)
for 45 min. Then, to quantify the mineralization, the wells
were washed twice and the dye was extracted with 10%
cetylpyridinium chloride (Sigma-Aldrich) in sodium phos-
phate buffer (Sigma-Aldrich). Absorbance was measured
at 560 nm in a plate reader.
2.16 Statistical analysis
For the Q-PCR validation and TNAP activity measure-
ments, the statistical analysis was conducted using Graph-
Pad Prism (Version 7.0) software. We used Mann-Whitney
U test for comparing two groups. P-values were repre-
sented by asterisks as follows: *P value < 0.05 and **P
value < 0.01. The mean values and standard error of the
mean were calculated.
3 RESULTS
3.1 Clinical trial design, safety, and
tolerability
Two patients fulfilling the inclusion/exclusion criteria
summarized in table 1 appearing in Figure 1A were
enrolled, P01 (6-year-old boy), affected by severe OI, and
P02 (8-year-old girl), affected by amoderate formofOI. The
patients received five MSCs infusions, 5-6 months apart,
which spanned 2.5 years (Figure 1B). Clinical and analyti-
cal evaluation (biochemistry, nutritional status, immunol-
ogy, hematology, and calcium phosphate metabolism),
bone parameters (fracture rates, BMD, and microstruc-
ture), and HRQoL, besides sera samples, were analyzed
before (basal), during (1 week, 1 month, and 4months after
each infusion), and after (follow-up period: 1 and 2 years
since the fifth and last MSCs infusion) the cell treatment
(Figure 1B). Among the clinical parameters monitoring,
immunological features were given thorough considera-
tion; in addition to immunoglobulins (IgG, IgM, and IgA),
anti-HLA, and antinuclear antibodies, the monocytes and
lymphocytes subsets (T, B, and NK) were analyzed find-
ing no alteration. Moreover, to ensure an absence of host
immune response to sibling MSCs, functional evaluations
based on in vitro MLR assay were performed prior to each
MSCs administration (Figure 1B). Donor HLA-matched
MSCs from siblings were co-cultured with PBMCs isolated
from patients without triggering the activation of the lat-
ter (Figure 1C). Additionally, co-culture of donor allogenic
MSCs with PBMCs stimulated with PHA resulted in an
inhibition of the proliferation of PHA-activated PBMCs
(Figure 1C).
Of note, the five reiterative infusions of MSCs were
well tolerated in both patients and there were no
treatment-related adverse events either during the cell
therapy, nor during the follow-up period.
3.2 Bone parameter outcomes
In accordance with their severe (P01) and moderate (P02)
OI, both patients had a significant number of reported frac-
tures from birth and through childhood: 15 in the case of
P01 (Figure 2A) and 11 in the case of P02 (Figure 2B). Dur-
ing the year prior to MSCs therapy, P01 had eight more
documented fractures, and P02 had two. Remarkably, dur-
ing the 2.5 years of cell treatment, P01 showed a reduction
in the number of fractures (three documented fractures),
whereas P02 reported only two fractures. Moreover, this
effect was maintained in both patients until the end of the
follow-up visits. In order to assess the effects of cell ther-
apy in the bone tissue of TERCELOI patients, lumbar spine
BMD was analyzed (Figure 2C). As expected, the basal
measurements of BMD in patients before the cell ther-
apy were in accordance with their OI severity. Thus, P01,
the most severe TERCELOI patient (6-year old), showed
a BMD of 0.336 g/cm2, which corresponds to healthy 2-
3 years’ old children.33 In contrast, P02 exhibited higher
basal BMD values: 0.736 g/cm2 that approximate the
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estimated BDM in normal healthy children of that age (8
years).33 Strikingly, both patients showed a substantial and
similar BMD increase trend after the first two MSCs infu-
sions (+0.043 and +0.047 for P01 and P02, respectively).
P01’s BMD remained steady after the first two infusions,
until the finalmeasurement (at the 2 years’ follow-up visit),
when he again showed an increase of 0.023 g/cm2. In the
case of P02, she showed a gradual improvement of BMD
during the duration of the cell therapy treatment, a trend
that was especially noticeable at the follow-up visits.
We also analyzed the trabecular bone microstructure
from right and left femoral distalmetaphysis of TERCELOI
patients, by using Quibim Precision Software, a quantita-
tive imaging tool (Figure 3A). This analysis showed general
improvements in the bonemicrostructure parameters. P02
showed an increase in the trabecular femoral bone vol-
ume (BV/TV) during the whole clinical trial period. P01
also showed an increase in BV/TV, which was especially
noticeable after five MSCs infusions, although this value
dropped in the last follow-up visit (Figure 3B). The trabec-
ular thickness (TbTh) remained constant throughout the
clinical trial; however, the trabecular separation (TbSp),
reflecting the mean size of trabecular pores in the bone,
showed a drastic drop in P01, which was especially notice-
able after the two first MSCs infusions (Figure 3C). In the
case of P02, with a lower basal TbSp value, this parameter
did not have a pronounced change. The trabecular number
(TbN) also showed improvements in both patients, with
a similar trend as that showed in BV/TV measurement:
P02 showed a continuous increase during the whole clin-
ical trial, whereas P01 showed an initial increase, which
subsequently fell by the 2-year follow-up visit (Figure 3D).
Finally, we studied the quality of trabecular structure
(QTS) of patients by using the QTS score, an index that
encompasses all the previous parameters analyzed. Both
patients showed improvements in the QTS score after cell
infusions (Figure 3E). Importantly, P02 finished the clini-
cal trial with a higher QTS than that showed before the cell
therapy. P01’s QTS values, however, returned to pretreat-
ment levels by the second follow-up. These negative out-
comes in the P01’s second follow-up visit indicated a dete-
rioration of bone microstructure. This circumstance was
consistent with the fact that in the 2-3months after the last
follow-up visit, P01 suffered three additional fractures.
Overall, these findings suggest that MSCs therapy had a
beneficial effect in the bone tissue of patients, leading to
a notable lower number of fractures, which was noticeable
from the early stages of treatment.Moreover, the decline in
some bone parameters in the second follow-up visits with
P01 suggests the necessity of continuous treatment, espe-
cially in the most severe patients.
3.3 Quality of life and achievements of
functional activities
Children with OI often struggle with chronic pain, even
during periods without fractures.34 This has a consider-
ably negative impact on quality of life, interfering with
daily activities and leading to poor mobility, missed school
days, and psychosocial stress. Thus, HRQoLmeasurement
in OI is essential to evaluate the clinical outcomes, espe-
cially those regarding cell-based therapies.35 To address
this point and evaluate functional improvements in TER-
CELOI patients, we used the PedsQL questionnaire, which
has been previously employed with OI pediatric patients
and their parents. This validated survey consists of 23
items in four functioning areas: physical, emotional, social,
and scholastic.14,36,37 The scores obtained from patients
and parents were quite similar across all the time points
assessed, denoting an internal consistency in the subjec-
tive perception of achieved improvements (Figure 4A).
In accordance with his more severe phenotype, before,
during, and after cell therapy, P01’s HRQoL was gen-
erally more affected (lower values) than P02’s. Overall,
both patients showed improvements in all the parameters
assayed from the beginning of cell therapy. Importantly,
this effect was maintained during the entire clinical trial,
with the exception of the 1-year follow-up visit in P02,
possibly associated with entry into early adolescence and
her coping with an acceptance of the illness. Psychologi-
cal support helped to overcome the situation as reflected in
the 2-year follow-up visit, which showed the highest scores
in all parameters assayed for both patients. During the
F IGURE 1 Overview of the TERCELOI clinical trial. (A) Table 1, reflecting the inclusion and exclusion criteria of the clinical trial. (B)
Diagram illustrating the clinical trial workflow. The five MSCs infusions administered in total period of time of 2.5 years are indicated (black
arrows). Previously to each cell infusion, mixed lymphocyte reaction assay was performed, denoted by asterisks. The visits for clinical and
analytical evaluation in addition to sera collection after each cell infusion are denoted by colored arrows. Before the cell therapy: red. During
the cell therapy: blue, 1 week (1 w); green, 1 month (1 m); and purple, 4 months (4 m) after each cell infusion. After the cell therapy: follow-up
visits at 1 and 2 years after the fifth cell infusion: gray. (C) Representative histogram plots of generations of divided cells as determined by
ModFit-LT software before the first MSCs infusion in P01 patient. Upper plots: controls consisted of unstimulated (left) or PHA-stimulated
PBMCs (right) isolated from P01. Dark blue peak in each plot indicates undivided parental cells. PHA-stimulated PBMCs show several cell
generations, denoting cell proliferation. Lower plots: P01 PBMCs cultured in the presence of donor MSCs, showing either no proliferation (left)
or suppressed proliferation under PHA stimulation (right)
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F IGURE 2 Bone-related parameters measured in OI patients
before, during, and after the MSCs therapy. (A and B) Number of
fractures in TERCELOI patients before the cell therapy: during the
perinatal period, childhood (from perinatal period up to 5-year old
in P01 and up to 7-year old in P02), and the year previous the first
infusion of MSCs; during the cell therapy treatment (each of the five
MSCs infusion is depicted) and during the follow-up visits (1 and 2
years after the fifth MSCs infusion); 1 w (1 week), 1 m (1 month), and
4m (4months) indicate the visits after each cell infusion. (C) BMD of
P01 (blue line) andP02 (orange line) before (0months), during (MSCs
infusions are specified with arrows), and after the cell therapy
treatment, there were remarkable clinical findings that
supported the improved outcomes of HRQoL of patients:
for example, P01 (6-year old) referred a significant percep-
tion of wellness and increase strength and mobility before
the third infusion of MSCs. Among several improvements,
it is worth mentioning that for the first time in life he was
able to roll, from lying on his back, to a prone position and
slide toward the edge of a sofa or bed and stand on his feet
for a few seconds. Likewise, P02 (8-year old) indicated that
she felt confident enough and had the strength to try phys-
ical activities (eg, try a cartwheel) for the first time in her
life after receiving the second infusion of MSCs.
Increased blood concentrations of GPLD1 have been
found in active (exercised) aged mice and healthy elderly
humanswhen compared to their sedentary counterparts.38
In fact, the administration of GPLD1 has been suggested
as a therapeutic approach providing the benefits of exer-
cise in old age.38 Interestingly, GPLD1 is also known to be
expressed in the developing bone ofmouse embryos.39 Tak-
ing these GPLD1 features into account, we tested whether
cell therapy could modulate GPLD1 levels in TERCELOI
patients, which showed improvements in the HRQoL and
in bone parameters during the clinical trial. Strikingly,
serum GPLD1 levels in P01 rose immediately (1 w and 1 m)
after the two first infusions and then dropped to base-
line levels 4 months later (4 m) (Figure 4B). In the case
of P02, this effect after the two first infusions was not as
remarkable as the one observed in P01, showing the high-
est GPLD1 levels 1 month after the third cell infusion.
3.4 Protein and miRNA screening in
sera from patients
To gain further insight into the cellular and molecular
mechanisms driven by cell therapy in TERCELOI patients,
we explored the possibility of a paracrine response induced
by infusedMSCs. Sera from patients were obtained before,
during, and after the cell therapy (Figure 1B). First, we
addressed an unbiased simultaneous screening of serum
protein expression. For this, we used a biotin label-based
antibody array technique, capable of detecting the expres-
sion of 1000 proteins covering a wide range of functions.
To perform this analysis, for each patient, we compared
the sera obtained after the first cell infusion collected at
1 week (1 w), 1 month (1 m), and 4 months (4 m) ver-
sus the basal serum (collected before the cell therapy).
Strikingly, 1 w and 4 m sera from P01 showed a great
increase in the expression levels of almost all the pro-
teins included in the antibody array when compared to
his basal serum levels (Figure 5A). Noticeably, this effect
was very pronounced in a subset of proteins from 1 m
serum, which exhibited a more than ninefold difference.
When analyzed with the Database for Annotation, Visual-
ization and Integrated Discovery (DAVID) software, these
proteins could be grouped into enriched categories related
to inflammatory response, angiogenesis, chemotaxis, col-
lagen catabolic process, and BMP, TGF-β, and JAK/STAT
signaling pathways (Table S1). In the case of P02, the
modulation of sera protein expression by MSCs therapy
was not as obvious, and the increase in fold change of
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F IGURE 3 Trabecular bone microarchitecture from TERCELOI patients before, during, and after the cell therapy. (A) Representative
image of QUIBIM software, indicating the ROI used to determine the different bone parameters in patients before (basal), after the two first
infusions (1 and 2 inf), after the three last infusions (3, 4, and 5 inf), and during the follow-up visits (1 and 2 y). (B) Percent (%) of bone (BVTV).
(C) Trabecular thickness (TbTh) and separation (TbSp). (D) Trabecular index (TBN). (E) Quality of trabecular structure (QTS). P01, blue color
lines; P02, orange color lines
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F IGURE 4 Quality of life and GPLD1 levels of patients during TERCELOI. (A) At that indicated time points: before (basal), during (after
the first, second, third, fourth, and fifth infusions), and after the MSCs therapy (1 and 2-year follow-up visits) questionnaires were performed to
each patient and his/her parents. The obtained numerical scores ranging from 0 to 100 have been depicted with a green color scale. (B) Serum
GPLD1 detection by ELISA in P01 (upper graph) and P02 (lower graph) at the mentioned time points
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differentially expressed proteins was modest (Figure 5B).
We found that more than 100 proteins were commonly
upregulated in sera from TERCELOI patients after the
cell therapy. QIAGEN Ingenuity Pathway Analysis (IPA)
showed that these upregulated proteins were grouped
in enriched functional categories related to “cell migra-
tion” and “cell survival,” which were predicted to be acti-
vated (positive z-score) (Figure 5C). Moreover, a subset of
proteins in the category “increased alkaline phosphatase
expression” was discovered, especially in the 1 m and 4 m
sera (Figures 5C and 5D). These findings suggest that the
MSCs infusion can induce a deep host systemic response,
especially in the most severe patient.
miRNAs are noncoding 22 nucleotide RNAs that repress
gene expression at the posttranscriptional level and can
play important roles in some diseases.40 In fact, specific
circulating miRNA profiles have been described to be
associated with increased risk of fragility fractures.41,42
Therefore, we decided to analyze the expression of
fracture-associated miRNAs in the sera of patients col-
lected before, during (1 month after each cell infusion),
and after theMSCs therapy (follow-up visits). In our study,
21 miRNAs known to be associated with high-risk of
fragility fractures were screened in P01 and P02 patients.
Before cell therapy, P01 basal serum showed a gener-
ally high expression of the assessed miRNAs (Figure 5E).
Strikingly, the expression of the great majority of these
miRNAs displayed a continuous and progressive downreg-
ulation during the cell therapy, and through the follow-
up visits. Of note, the higher downregulation of miRNAs
expression was achieved after the fifth MSCs infusion. In
the case of P02, the miRNAs’ expression pattern before
cell therapy was in general terms the opposite as that
shown by P01, and thus the majority of the miRNAs
were slightly downregulated (Figure 5E). Moreover, the
cell therapy did not show a noticeable change in miRNAs
expression, becausemiRNAs’ downregulation remained in
the follow-up visits. Even so, there were some miRNAs,
known to play specific roles as osteogenesis inhibitors,
whose expression in the follow-up visits were even lower
than before the cell therapy: miR188-5p, miR214-3p, and
miR375.43–45
3.5 Functional analysis of sera from
patients in OI MSCs
Having observed protein and microRNAs expression
changes in patients’ sera after cell therapy, we wondered
whether these sera could be pro-osteogenic, which would
be consistent with the improvements in bone phenotypes
observed in patients after MSCs administration. To assess
this possibility in vitro in the context of OI disease, we iso-
lated MSCs from bone tissue samples from 10 OI pediatric
patients (OI MSCs) who underwent correcting surgery.
Isolated OI MSCs showed plastic adherence and a typi-
cal fibroblast spindle-shaped morphology and a panel of
cell surface markers that were in accordance with the
immunophenotype defined for MSCs (Figure S1A). Their
identity as progenitors of osteoblasts was confirmed by
the extracellular matrix mineralization (increased calcium
deposits), a feature of late osteogenesis,46 shown by OI
MSCs after 21 days of osteogenic differentiation (Figure
S1B). To study the early effects of sera from TERCELOI
patients and elucidate if post-cell therapy sera could have
an effect on directing osteogenic fate of MSCs, we con-
ducted a transcriptomic study based on RNA sequencing
experiments (RNAseq). In this way, we compared the gene
expression profiles from differentiated OI MSCs (10 OI
MSCs lines) cultured in the presence of serum from P01
collected before the therapy (basal) versus the P01 serum
collected 1 month (1 m) after the first cell infusion from
the same patient. We considered that a gene was differ-
entially expressed, when at least nine of the 10 cell lines
analyzed showed consistent and significant (P-value< .05)
changes in its expression. Following these strict criteria,
we found that when compared to basal serum, 1 m serum
modulated the expression of 117 transcripts: 52 upregu-
lated and 65 downregulated (Figure 6A-C). These RNAseq
results were validated by quantitative PCR: ANGPTL4
and PDK4, classical targets of the adipogenic transcrip-
tion factor PPARγ,47 showed a downregulation, whereas
the metabolic enzyme ADH1B and the FGF7 growth fac-
tor showed an upregulation upon cell culture of OI MSCs
with 1 m serum (Figure 6D). Interestingly, analysis of
the canonical pathways of genes dysregulated by IPA
F IGURE 5 Expression analysis of proteins and miRNAs in sera of patients. (A and B) Antibody arrays quantification of serum proteins
in TERCELOI patients. The dot plots reflect the expression fold induction of the 1000 proteins included in both arrays (493 and 507) after the
first MSCs infusion (1 w, green color; 1 m, red color; 4 m, blue color) when compared to the expression of those proteins before the cell therapy
(black, dashed line). Each dot represents a protein. (C) IPA comparison analysis for commonly upregulated proteins (fold change > 1.3) after
the first MSCs infusion (1 w, 1 m, and 4 m) in P01 and P02. The heatmap represents the significantly enriched (P < .05) biological functions
predicted to be activated (z-score > 2) or inhibited (z-score < 2). (D) Activation network diagram for TNAP predicted by IPA based on five
proteins found to be upregulated in P01 and P02 1 month after the first cell infusion. (E) Heatmap of the miRNAs expression signature of P01
and P02 serum samples, before, during (1 month after each cell infusion), and after (1 and 2 years’ follow-up) cell therapy. Unit variance scaling
was applied to the global mean normalized expression values for each miRNA. Color indicates relative upregulation (red) or downregulation
(blue) for each miRNA (row)
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F IGURE 6 Transcriptome changes in OI MSCs in the presence of sera from P01 patient. (A and B) Heatmaps reflecting the significantly
DEGs (rows) identified in the 10 OI MSCs (columns, each cell line identified by a number and a color) by RNAseq. The results were obtained
comparing the data from OI MSCs cultured under osteogenic conditions (4 days) in the presence of the serum collected after the cell therapy
(first infusion + 1 month) versus the serum collected before the treatment (basal). Numbers indicate the FPKM reads obtained from RNAseq
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predicted an activation (positive z-score) of “endothelin-
1 signaling” process, which is known to induce in vitro
proliferation and differentiation of osteoprogenitors and
in vivo trabecular bone formation (Figure 7A).48–50 “Gly-
colysis,” a major feature of osteogenic differentiation,51
was also identified as enriched. Conversely, the IL-8 sig-
naling pathway, which plays a central role in angiogene-
sis and inflammation,52 was identified as downregulated.
Bone-related categories such as “osteoarthritic pathway”
and “role of osteoblasts in rheumatoid arthritis” were also
identified as enriched among the DEGs (Figure 7A). DEGs
were further analyzed with DAVID software (Figure 7B).
MSCs undergoing osteogenic differentiation, even at early
stages, are defined by the production of extracellular
matrix proteins.53 Consistent with this fact, the most sig-
nificantly enriched category identified by DAVID among
the upregulated DEGs was “extracellular matrix” (P-value:
1.69 × 10−5) (Figure 7B). Other categories related to “colla-
gen binding,” “oxidoreductase activity,” and “unsaturated
fatty acid biosynthesis” were also enriched (Figure 7B).
Among the downregulated DEGs, categories related to
“hypoxia,” “angiogenesis,” and “collagen metabolic pro-
cess” were found to be significantly enriched (Figure 7B).
To identify potential transcription factors driving the gene
expression changes upon cell culture with serum obtained
after cell therapy, the DEGs were further analyzed using
the upstream regulator analysis in IPA. Strikingly, the top
upstream regulators predicted to be inhibited were the
pro-adipogenic transcription factor PPARGC1A (P-value:
2.45 × 10−9; z-score: –1.507) (Figure 7C),53 CEBPA, also
pro-adipogenic (P-value: 8.53 × 10−5; z-score: –1.03), and
FOS (P-value: 4.35 × 10−6; z-score: –1.03), identified previ-
ously as inhibited during osteogenesis of MSCs.53 On the
contrary, the top transcription factor predicted as activated
was the pro-osteogenic SMARCA4 (P-value: 2.89 × 10−6; z-
score: +1.394),54 followed by SOX2 (P-value: 2.50 × 10−5;
z-score: 1.327) and TEAD3 (P-value: 8.03 × 10−5; z-score:
+1.00). Collectively, these results suggest that P01 serum
obtained 1 month (1 m) after the first cell infusion was able
to activate an early pro-osteogenic program inOIMSCs, by
activating pro-osteogenic transcription factors and inhibit-
ing pro-adipogenic ones.
We then evaluated the potential of TERCELOI sera on
directing osteogenic fate of MSCs, by the determination
of the activity of TNAP, an early marker of osteogenic
differentiation.46 We cultured eight independent OI MSCs
lines under osteogenic differentiation in the presence of
basal serum, or sera collected after the first MSCs infusion
in TERCELOI patients: 1 w, 1 m, and 4 m. TNAP activity
wasmeasured at day 4 of cell differentiation. Strikingly, 1m
serum fromP01 significantly enhancedTNAPactivity (Fig-
ure 7D, left), whereas sera from P02 did not affect TNAP
activity in OI MSCs (Figure 7 D, right). Finally, we ana-
lyzed the potential of TERCELOI sera to induce the min-
eralization of OIMSCs lines. Strikingly, 1 m sera from both
patients showed a great ability to induce mineralization
of OI MSCs (enhanced calcium deposits), whereas basal
serum did not (Figures 7E and 7F).
4 DISCUSSION
The transitory nature of the clinical benefits observed after
MSCs therapy (one or two MSCs infusions) in OI patients
is a major drawback of this treatment approach.15,16,19,20 In
TERCELOI, we have faced the previously described short-
termeffects ofMSCs therapy by performing repeatedMSCs
infusions in patients. To avoid subjecting the patients
to alloimmunization after repeated exposure to non-self
MSCs, donor MSCs were HLA-identical or histocompat-
ible (five shared out of six HLA antigens). That level of
histocompatibility was enough to accomplish the security
of the five consecutive cell infusions in a period of 2.5
years with beneficial outcomes in both patients. Regard-
ing the mechanism of action of cell therapy in OI, molec-
ular and cellular studies have led to a change of paradigm,
from the initially expected host tissue replacement of dead
or injured cells by donor MSCs to the current paracrine
hypothesis.15,16 In fact, growing evidence from animal
models of OI and other diseases suggests that MSCs exert
their therapeutic effects, at least in part, via paracrine
mechanisms.21,22,55,56 In this way, the significance of our
study is twofold: this is the first clinical trial testing the
safety and effectivity of reiterative MSCs infusions in two
nonimmunosuppressed OI pediatric patients, which at the
same time, by studying the patients’ sera composition,
begins to unravel themode of action ofMSCs inOI disease,
a deficit in understanding previously recognized.57
Each enrolled OI patient showed a different severity:
P01, with a very severe phenotype, and P02, withmoderate
clinical manifestations. The limited number of patients
enrolled in TERCELOI was due to the highly restricted
inclusion criteria required in the domestic pediatric
patients affected by this rare bone disorder. After receiving
for each DEG in each cell line. The columns “F” and “A” of the table denote how many votes are Favor and Against the analyzed condition,
respectively. (C) Genome browser screenshot of RNAseq tracks at ADH1B and PDK4 loci in the 10 OI MSCs lines analyzed, cultured under
basal or 1 month after the first cell infusion serum. (D) Quantitative PCR validation of a subset of genes in the 10 OI MSCs lines. Each color
represents an OI MSCs line. **P < .01
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F IGURE 7 Assessment of the pro-osteogenic potential of sera from TERCELOI patients. (A) IPA gene ontology enrichment analysis of
the DEGs identified by RNAseq. (B) Significantly enriched biological processes identified by DAVID database. (C) Top six (three activated,
z-score > 1; three repressed, z-score < 1) upstream regulators predicted by IPA to be responsible for the DEGs. Each transcription factor is
represented by a sphere and plotted by its z-score value. The P-values for each transcription factor are graphically represented by different
sphere sizes. (D) TNAP activity was measured (right graph) at day 4 of osteogenic induction in sera collected before (basal serum) and at
different time points after the first cell infusion (1 w, 1 m, and 4 m). Each dot represents the TNAP activity value for an OI MSC cell line (n = 8,
*P < .05). Horizontal lanes represent the mean of TNAP for each condition, two independent experiments). (E) Representative alizarin red S
staining (ARS) staining of two OIMSCs lines cultured under osteogenic conditions (14 days) in the presence of TERCELOI sera collected before
(basal) and 1 month after the first cell infusion. A field with a higher magnification shows the stained calcium deposits for each condition.
Scale bar: 100 μm. (F) ARS quantification from triplicate wells of OI MSCs lines (n = 2) cultured with P01 or P02 sera. The mean and SEM was
calculated from triplicates for each condition. Presented are representative data from two independent experiments
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five histocompatible MSCs infusions during a period of
2.5 years and followed an additional 2 years after the final
cell infusion, neither of the patients suffered any adverse
effects. Moreover, along the cell treatment (including the
additional 2-year follow-up period), both patients showed
durable improvements regarding the number of bone
fractures and morphometric bone parameters, leading
to a better HRQoL, which was noticed by patients and
parents. In fact, patient-reported outcome measures, such
as the HRQoL, have been recently strongly recommended
to be a highly valuable tool when assessing functional
improvements in musculoskeletal disorders, especially
those regarding cell-based therapies.35 Regarding the clin-
ical evaluation, despite the difficulty of extracting rigorous
conclusions from what the families/parents experienced
and related, in both cases it was remarkable that the
patients dared to try new activities or games for the first
time in their lives, feeling stronger, more optimistic, and
confident besides with less fear of suffering a fracture. Of
note, these improvements were especially noticeable after
the two first MSCs infusions. This observation was sup-
ported in parallel with the study of bone tissue parameters:
the major BMD increase as well as bone microstructure
parameters such as TbSp, TbN, and QTS were observed in
both patients after the two first infusions.
Amajor finding of our study, fromamechanistic point of
view, is the existence of a systemic pro-osteogenic response
in OI patients as a consequence of MSCs therapy, which
could be cause or consequence of the reported clinical
improvements of patients. In that way, the cell therapy was
able to elevate the serum levels of a therapeutic molecule
recently shown to be increased in active healthy aging and
known to be present in the developingmouse skeleton,38,39
GPLD1. In fact, we detected a rise in GPLD1 levels as
early as 7 days after the first cell infusion, especially in
P01, who in addition showed this trend after the second
infusion.
Our unprecedented patient’s data about the mechanism
of action of MSCs therapy suggest that the efficacy of the
paracrine response induced by MSCs could depend on
the severity of OI disease. Thus, the clinical benefits were
more noticeable (reduction in number of fractures during
and after the MSCs treatment) and with quite remarkable
molecular findings (sera composition, miRNAs modula-
tion, and increased TNAP activity) during and after cell
therapy in P01, the most severely affected patient. Inter-
estingly, basal serum from P01 showed a marked upreg-
ulation of the expression of almost all the miRNAs ana-
lyzed, which have been associated to osteoporotic bone
fractures,45 but not P02. A number of recent studies have
demonstrated a causative role for the dysregulation of cer-
tain miRNAs in bone disorders such as osteoporosis. MiR-
375 and miR-214-39, found to be significantly upregulated
in basal serum from P01, have been shown to be upreg-
ulated in serum from osteoporosis patients with verte-
bral fractures.44,45 Moreover, miR-214-3p was reported to
be secreted in exosomes by osteoclasts and transferred
to osteoblasts inhibiting osteoblastic bone formation.44
The overexpression of osteoporosis-related miRNAs in P01
basal serum probably is a reflection of themost severe phe-
notype exhibited by this patient. Encouragingly, the reit-
erative MSCs infusions were able to modulate and finally
repress this initial u-regulation of miRNAs in P01. This
interesting result suggests that at least at the miRNA level,
the effect ofMSCs infusion could not only be transitory but
also cumulative because there is a gradual improvement
with each cell infusion, the results of which last for at least
2 years after the final infusion. Moreover, our study reveals
the potential enhanced expression of specific circulating
miRNAs in the context of severe OI disease, a matter
scarcely addressed in the literature.58 All in all, our data
suggest that in severely affected patients, the upregulation
of these miRNAs could be modulated and restored by con-
tinuous cell therapy.
Strikingly, when functionally challenged, sera from
patients obtained after cell therapy showed pro-osteogenic
capabilities, which were more pronounced in the case of
P01 serum. Thus, gene expression analysis showed a poten-
tial shift toward the osteogenic lineage (to the detriment
of the adipogenesis process) when OI MSCs were cultured
in the presence of serum collected after the first cell infu-
sion. Consistent with this finding, TNAP activity, an early
marker of osteogenesis, was enhanced in these cells. Strik-
ingly, mineralization was also induced in OI MSCs cul-
tured with sera from both TERCELOI patients collected
after the cell therapy. Collectively, molecular and func-
tional data obtained from sera analysis support the clini-
cal benefits observed in OI pediatric patients treated with
repeated infusions of HLA-matched MSCs, indicating the
activation of a pro-osteogenic paracrine response as conse-
quence of cell therapy.
How MSCs therapy modulates the levels of serum pro-
teins and miRNAs in OI patients remains unknown, but
it could be due to the paracrine properties of the MSCs.
In fact, there are publications supporting this observation:
the exosome secretion exerted by infusedMSCs in amouse
model of lupus erythematosus was shown to be the under-
lyingmechanism governing the improvement of the osteo-
porotic phenotypes in thesemice.55 Moreover, the infusion
of MSCs-derived extracellular vesicles was shown to be
responsible for improving bone growth in a mouse model
of OI.22
Currently, an emerging concept is gaining attention,
specifically the priming of MSCs to adapt their responses
depending on the microenvironment they face.59 In
TERCELOI, we have addressed the in vitro priming of
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MSCs with specific factors from the OI microenvironment
(serum obtained before and after the cell therapy), find-
ing that the osteogenic potential of MSCs can be enhanced
with serum obtained after cell therapy. In this way, the in
vivo bone healing potential of MSCs could be improved
after being primed. Our results suggest that the greatest
OI severity of P01 could be the underlying reason mediat-
ing his enhanced clinical and molecular outcomes. Thus,
the most severe microenvironment in P01 (ie, upregula-
tion of miRNAs) could be triggering amore efficient MSCs
response in the interest of bone healing. In fact, a previ-
ous work demonstrated that in vitro MSCs priming with
plasma coming from oim mice, a model of severe OI, led
to increased chemotaxis and engraftment of transplanted
MSCs in mice bones when compared to that shown by
MSCs primed with control mice serum.60
5 CONCLUSIONS
In conclusion, and taking into account the limited num-
ber of patients, we can infer from the TERCELOI results
that repeatedMSCs therapy in pediatric patients is feasible
and safe, supporting recent cell therapy attempts to other
disorders based on sequential cell infusion.61–63 Regard-
ing the effectiveness and mode of action of MSCs therapy,
clinical improvements and noticeable pro-osteogenic sys-
temic response were detected as soon as the OI patients
received the first cell infusion. Moreover, the clinical ben-
efits persisted throughout thewhole cell therapy treatment
and up to the 2-year follow-up visit. However, some bone
microstructure parameters, startedworsening in the 2-year
follow-up visit, suggesting repeated long-term infusions
are required to maintain the clinical benefits, especially in
the more severe patients. In accordance with this observa-
tion, it is worth noting that after the 2-year follow-up visit,
in the next couple of months P01 suffered three additional
fractures.
For the future, detailed studies addressing the prim-
ing of MSCs in an OI specific context will elucidate if
the most severe microenvironments (severe OI serum)
could trigger different functions on MSCs. Secretomes
from these primed MSCs, more easily obtained and free of
the immune match requirements of MSCs, could be con-
sidered to be relevant surrogates of cell therapy (therefore
democratizing the treatment), especially for chronic dis-
eases such as OI.
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